BCI-952

BrainCells is outliciensing BCI-952, a fixed dosage combination of buspirone and melatonin.

Highly Neurogenic Compound Targets Depression and Cognition

BrainCells identified this fixed dose combination by screening over 1,000 compounds that, combined, presented over 150 different mechanisms. This particular combination:

Showed neurogenic effects on human neural stem cells in vitro
Confirmed neurogenesis in vivo, and
Confirmed activity in behavioral models for depression

Clinical Results

A Phase II investigator initiated trial was completed in 2009 and evidenced activity in patients suffering from depression. Read press release »